Cargando…

Effect of JAK1/2 inhibition on High-Output Heart Failure Associated With Myeloproliferative Disease

Detalles Bibliográficos
Autores principales:	Fujii, Yuki, Takei, Makoto, Hayashi, Risa, Yagi, Ryuichiro, Kawano, Megumi, Endo, Ayaka, Suzuki, Kenji, Hirata, Naoki, Hasegawa, Tasuku, Takahashi, Toshiyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Clinical Case Challenges
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352270/ https://www.ncbi.nlm.nih.gov/pubmed/34396239 http://dx.doi.org/10.1016/j.jaccao.2020.02.018

Ejemplares similares

Critical Roles of Myc-ODC Axis in the Cellular Transformation Induced by Myeloproliferative Neoplasm-Associated JAK2 V617F Mutant
por: Funakoshi-Tago, Megumi, et al.
Publicado: (2013)

Mouse models of myeloproliferative neoplasms: JAK of all grades
por: Li, Juan, et al.
Publicado: (2011)

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
por: de Freitas, Renata Mendes, et al.
Publicado: (2015)

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
por: Vainchenker, William, et al.
Publicado: (2018)

Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2020)

JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
por: Bader, Michael Stephan, et al.
Publicado: (2022)

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
por: Passamonti, Francesco, et al.
Publicado: (2011)

The JAK2 gene as a protagonist in chronic myeloproliferative neoplasms
por: de Freitas, Renata Mendes, et al.
Publicado: (2013)

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)

JAK2 and Beyond: JAK2V617 Mutational Study of Myeloproliferative Disorders and Haematological Malignancies
por: Syeed, Nidda
Publicado: (2019)

Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms
por: Goldin, Lynn R, et al.
Publicado: (2009)

JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms
por: Ma, Wanlong, et al.
Publicado: (2010)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
por: Hassan, Abdulaziz, et al.
Publicado: (2015)

Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
por: Sapre, Manali, et al.
Publicado: (2019)

The Contribution of JAK2 46/1 Haplotype in the Predisposition to Myeloproliferative Neoplasms
por: Paes, Jhemerson, et al.
Publicado: (2022)

Suppression of multiple anti‐apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms
por: Takei, Hisashi, et al.
Publicado: (2021)

JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms
por: Bellido, Mar, et al.
Publicado: (2012)

Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms
por: Čokić, Vladan P., et al.
Publicado: (2015)

The role of the Exon 13 G571S JAK2 mutation in myeloproliferative neoplasms
por: Bahar, Burak, et al.
Publicado: (2016)

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
por: Helbig, Grzegorz
Publicado: (2018)

The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random?
por: Anelli, Luisa, et al.
Publicado: (2018)

Two Cases of Severe Hypertension in JAK2 Mutation-Positive Myeloproliferative Neoplasms
por: Rao, Raunak, et al.
Publicado: (2020)

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
por: Gäbler, Karoline, et al.
Publicado: (2013)

JAK out of the box: myeloproliferative neoplasms--associated JAK2 V617F mutations contribute to aortic aneurysms
por: Elf, Shannon E.
Publicado: (2021)

Clinical characteristics and management of headache in patients with myeloproliferative neoplasms
por: Shimoyama, Takashi, et al.
Publicado: (2022)

JAK2 V617F: A Single Mutation in the Myeloproliferative Group of Disorders
por: McLornan, Donal, et al.
Publicado: (2006)

Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms
por: Stein, Brady L., et al.
Publicado: (2011)

Splanchnic vein thrombosis, the onset manifestation in JAK positive Chronic Myeloproliferative Disorders Neoplasms
por: Vladareanu, AM, et al.
Publicado: (2011)

Jak2V617F myeloproliferative neoplasm stem cells and interferon-alpha
por: Lane, Steven W., et al.
Publicado: (2013)

Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms
por: ZHANG, SHU-PENG, et al.
Publicado: (2015)

JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
por: McKenney, Anna Sophia, et al.
Publicado: (2018)

JAK2 exon 12 mutation-positive myeloproliferative neoplasm associated with recurrent thromboembolism
por: Tavakoli, Vahid, et al.
Publicado: (2017)

SAT-091 Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
por: Sapre, Manali, et al.
Publicado: (2019)

AXL Inhibition Extinguishes Primitive JAK2 Mutated Myeloproliferative Neoplasm Progenitor Cells
por: Pearson, Stella, et al.
Publicado: (2019)

JAK2 Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms
por: Torres, Dania G., et al.
Publicado: (2022)

JAK2 V617F-Dependent Upregulation of PU.1 Expression in the Peripheral Blood of Myeloproliferative Neoplasm Patients
por: Irino, Tamotsu, et al.
Publicado: (2011)

Integrating information from existing databases for enhanced function annotation of genes, genomes and networks
por: Tripathi, Lokesh Pati
Publicado: (2007)

Alternative splicing: a paradoxical qudo in eukaryotic genomes
por: Kashyap, Luv, et al.
Publicado: (2007)

SMARThivCD4mos: A complexity-free and cost effective model technology for monitoring HIV patients CD4 number in resource-poor settings
por: Yari, Aboubakar, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_96rau176jaqbc620ugjvllir79